Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Drugs. 2022 Apr;82(6):691-695. doi: 10.1007/s40265-022-01700-8.
Gefapixant (Lyfnua; Merck & Co.) is a first-in-class, non-narcotic, selective P2X3 receptor antagonist being developed for the treatment of refractory chronic cough or unexplained chronic cough. Marketing approval for gefapixant is being sought in the EU and USA, and the drug was recently approved for marketing in Japan as treatment for refractory or unexplained chronic cough. This article summarizes the milestones in the development of gefapixant leading to this first approval.
吉法替尼（Lyfnua；默克公司）是一种首创的、非类阿片的、选择性 P2X3 受体拮抗剂，正在开发用于治疗难治性慢性咳嗽或不明原因的慢性咳嗽。正在欧盟和美国寻求吉法替尼的营销批准，该药物最近在日本获得批准用于治疗难治性或不明原因的慢性咳嗽。本文总结了导致首次批准的吉法替尼开发的里程碑。
